| Document |
Document Title |
|
WO/2024/070946A1 |
The present invention provides a composition for semiconductor devices which has the excellent ability to remove dry-etching residues and is more inhibited from causing the dissolution of tungsten and which, when works are treated therew...
|
|
WO/2024/058602A1 |
The present invention relates to a compound and a method for identifying impurities included therein.
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/051825A1 |
Provided are a cationic lipid and a preparation method therefor, a lipid composition containing the cationic lipid, and an LNP-pharmaceutical composition containing the lipid composition and a preparation of the LNP-pharmaceutical compos...
|
|
WO/2024/032611A1 |
Provided is a drug delivery system, which in particular relates to a lipid composition. The shown lipid composition comprising a therapeutic agent and/or a prophylactic agent such as RNA can be used for delivering the therapeutic agent a...
|
|
WO/2024/032754A1 |
Disclosed are a nitrogen-containing chain compound, a preparation method therefor, a composition containing said compound, and a use thereof. Provided is a nitrogen-containing chain compound as represented by formula (I) or a pharmaceuti...
|
|
WO/2024/027789A1 |
Disclosed are a cationic lipid compound as represented by formula (I) and composition for nucleic acid delivery, and a use. Also disclosed are a use of nano-lipid particles using said compound as a key component in the aspect of nucleic ...
|
|
WO/2023/239836A9 |
Disclosed herein are novel lipids, lipid nanoparticles and their uses for the transport of therapeutic agents to a subject, or for the treatment and/or prophylaxis of diseases in the subject.
|
|
WO/2024/019936A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2024/017254A1 |
The present application relates to an amino lipid compound having the following structural formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, and use thereof as a component of a lipid nanoparticle preparation for ...
|
|
WO/2024/014430A1 |
The present invention addresses the problem of providing a method for producing an amino lipid compound that has improved yield in a carbonate esterification reaction and to provide an intermediate compound to be used in the abovemention...
|
|
WO/2024/010032A1 |
The purpose of the present invention is to provide an amino-group-containing polyfunctional (meth)acrylate composition that contains an amino-group-containing polyfunctional (meth)acrylate with high purity and that has a low coloration d...
|
|
WO/2023/250197A2 |
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, st...
|
|
WO/2023/246074A1 |
Provided in the present invention are a cationic lipid compound used for nucleic acid delivery, a composition and a use. The compound is as shown in the following formula (I). Further provided in the present invention are the use of the ...
|
|
WO/2023/249926A2 |
Fluorinated monomer compositions having the formula: A-L-Z (1), wherein A is a polymerizable group (e.g., a vinyl group); L is a bond or linking portion; Z is a zwitterionic moiety or a zwitterionic precursor moiety containing a protecti...
|
|
WO/2023/246747A1 |
Provided in the present invention are a cationic lipid compound and a composition for delivery of a nucleic acid, and the use. The compound is represented by the following formula (I). Further provided in the present invention are the us...
|
|
WO/2023/235976A1 |
A polycation carrier particle obtained by the polymerization of a multiacrylate monomer with one or more hydrophilic monomers to form crosslinks. The polycation carrier particle has a net positive electric charge. The multiacrylate monom...
|
|
WO/2023/229295A1 |
The present invention relates to a phenylpropene derivative, and a pharmaceutical composition for the prevention or treatment of cancer, comprising the phenylpropene derivative as an active ingredient. The phenylpropene derivative disclo...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/202554A1 |
Disclosed are a chiral aryl propionic acid derivative and a pharmaceutical composition thereof, and a use. The chiral aryl propionic acid derivative is as shown in formula (I), and the definition of each group is given in the description...
|
|
WO/2023/186041A1 |
Disclosed are a cationic lipid compound, and a preparation method therefor and use thereof. Hydroxyl is introduced into the cationic lipid compound at the head, and meanwhile, the overall structure is similar to a cone with a small head ...
|
|
WO/2023/186167A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle containing the cationic lipid, and use of the c...
|
|
WO/2023/186171A1 |
Disclosed is a cationic lipid having the following general formula (I), wherein A, B, C, and D are each as defined in the description. Also disclosed are a liposome and a lipid nanoparticle comprising the cationic lipid, and use of the c...
|
|
WO/2023/188830A1 |
The present invention provides lipid nanoparticles each containing a pH-sensitive cationic lipid represented by formula (I) [wherein a represents an integer of 3 to 5; b represents 0 or 1; R1 and R2 each independently represent a group r...
|
|
WO/2023/179463A1 |
The present invention relates to a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which relate to the technical field of medical biology. The problem of there being an urgent need...
|
|
WO/2023/179462A1 |
Disclosed in the present invention are a cationic lipid compound, a preparation method therefor and the use thereof, and an mRNA delivery system, which solve the problem of there being an urgent need to develop cationic lipids with high ...
|
|
WO/2023/179497A1 |
The present invention belongs to the field of gene drug delivery, and particularly relates to a lipid compound, a lipid carrier based on the lipid compound, a nucleic acid lipid nanoparticle composition and a pharmaceutical formulation. ...
|
|
WO/2023/173203A1 |
Provided herein is a method for a method for producing an ionizable amino lipid, or a pharmaceutically acceptable salt thereof, the method comprising a nucleophilic displacement of a leaving group L in a compound of Formula (II), wherein...
|
|
WO/2023/168484A1 |
Compounds of Formula (A) and methods for use as agricultural chemicals, including herbicides: Formula (A)
|
|
WO/2023/160702A1 |
The present disclosure relates to an amino lipid compound, a preparation method therefor, a composition thereof and the use thereof. Specifically, the present disclosure relates to an amino lipid compound represented by formula (I) or a ...
|
|
WO/2023/164544A2 |
Provided herein, inter alia, novel ionizable cationic lipids, lipid nanoparticles comprising the novel ionizable cationic lipids and methods of using said nanoparticles.
|
|
WO/2023/143601A1 |
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is foun...
|
|
WO/2023/143600A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipi...
|
|
WO/2023/143591A1 |
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has bet...
|
|
WO/2023/141624A1 |
Ionizable lipids and lipid nanoparticles comprising ionizable lipids are provided herein. Also provided are methods for making and using the lipid nanoparticles for delivery to a cell one or more payload agents, including polypeptides, m...
|
|
WO/2023/134325A1 |
A lipid compound, a composition containing same, and a use, the lipid compound being prepared by means of a ring-opening reaction of organic amine and glycidyl ester, and the structure not containing free amino groups. The lipid compound...
|
|
WO/2023/136689A1 |
The present invention relates to a novel ionizable lipid containing a biodegradable ester bond. The ionizable lipid containing an ester bond, according to the present invention, stably delivers an anionic drug when prepared into lipid na...
|
|
WO/2023/121971A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/121965A1 |
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
|
|
WO/2023/113456A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/113457A1 |
The present invention relates to a compound capable of degrading a target protein by using ubiquitination, and provides a compound having a targeted protein binding moiety (TBM) structure, which binds to a target protein or polypeptide, ...
|
|
WO/2023/112939A1 |
A method for purifying a composition that comprises a step for dissolving the composition containing a compound represented by formula(1) [in formula (1): R1 represents -N(R2)-R2 (wherein R2 represents a C1-C4 alkyl group); R3 and R4 rep...
|
|
WO/2023/114188A1 |
Provided herein are compounds, such as compounds of Formula (I), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, and isotopically labeled derivatives thereof, and compositions...
|
|
WO/2023/103734A1 |
Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The ...
|
|
WO/2023/103733A1 |
Disclosed are a cannabidiol derivative, and a preparation method therefor and the use thereof, and in particular the use thereof in the prevention and treatment of a nervous system disease (such as epilepsy and Parkinson's disease). The ...
|
|
WO/2023/098670A1 |
Disclosed are a polyphenol antioxidant and a preparation method therefor and an application thereof. An antioxidant molecule designed in the present invention contains a hindered phenol functional group used as a main antioxidant, and fu...
|
|
WO/2023/083983A1 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2023/083291A1 |
The present invention relates to compounds of formula I and formula II and the use thereof in the treatment of metabolic diseases such as liver fibrosis and non-alcoholic hepatitis. Specifically, provided are the compounds as shown, and ...
|
|
WO/2023/061460A1 |
Provided is a novel cationic lipid having a structure as represented in general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pha...
|
|
WO/2023/061999A1 |
The present invention discloses a distinct mode of action of a nickel catalyst to forge C-0 bonds to unlock the mild utilization of N2O as O-atom transfer reagent in the synthesis of complex phenols from the corresponding aryl halides.
|
